

Scott B Halstead

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6136912/publications.pdf>

Version: 2024-02-01

144
papers

14,603
citations

23567

58
h-index

20358

116
g-index

281
all docs

281
docs citations

281
times ranked

9697
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Dengue Vaccine Protection Possible?. <i>Clinical Infectious Diseases</i> , 2022, 74, 156-160.	5.8	8
2	Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. <i>BioDrugs</i> , 2021, 35, 505-515.	4.6	16
3	NS1, Dengue's Dagger. <i>Journal of Infectious Diseases</i> , 2020, 221, 857-860.	4.0	6
4	COVID-19 Vaccines: Should We Fear ADE?. <i>Journal of Infectious Diseases</i> , 2020, 222, 1946-1950.	4.0	55
5	Ethics of a partially effective dengue vaccine: Lessons from the Philippines. <i>Vaccine</i> , 2020, 38, 5572-5576.	3.8	43
6	A Step in the Right Direction. <i>Journal of Infectious Diseases</i> , 2020, 222, 712-714.	4.0	0
7	COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. <i>Frontiers in Immunology</i> , 2020, 11, 1196.	4.8	10
8	Severe dengue in travellers: pathogenesis, risk and clinical management. <i>Journal of Travel Medicine</i> , 2019, 26, .	3.0	86
9	Dengue infection and advances in dengue vaccines for children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 734-741.	5.6	29
10	A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	32
11	Travelling arboviruses: A historical perspective. <i>Travel Medicine and Infectious Disease</i> , 2019, 31, 101471.	3.0	14
12	Japanese encephalitis vaccine for travelers: risk-benefit reconsidered. <i>Journal of Travel Medicine</i> , 2019, 26, .	3.0	16
13	Recent advances in understanding dengue. <i>F1000Research</i> , 2019, 8, 1279.	1.6	63
14	Is Dengvaxia a useful vaccine for dengue endemic areas?. <i>BMJ: British Medical Journal</i> , 2019, 367, l5710.	2.3	23
15	Insights from direct studies on human dengue infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17-19.	7.1	13
16	Cause and consequence of loss in vaccine trust. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 628-629.	3.3	3
17	Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2158-2162.	3.3	55
18	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a030700.	5.5	37

#	ARTICLE	IF	CITATIONS
19	Dengue Vaccines. , 2018, , 241-251.e6.		2
20	Japanese Encephalitis Vaccines. , 2018, , 511-548.e12.		8
21	Nguyen Trong Lan, MD, PhD. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1117-1117.	1.4	0
22	Zika enhancement: a reality check. Lancet Infectious Diseases, The, 2017, 17, 686-688.	9.1	11
23	Consider stopping dengvaxia administration without immunological screening. Expert Review of Vaccines, 2017, 16, 301-302.	4.4	36
24	Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine, 2017, 35, 6355-6358.	3.8	159
25	Use of the live attenuated Japanese Encephalitis vaccine SA 14a€“14a€“2 in children: A review of safety and tolerability studies. Human Vaccines and Immunotherapeutics, 2017, 13, 2222-2231.	3.3	23
26	Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infectious Diseases, The, 2017, 17, e378-e382.	9.1	29
27	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	3.8	81
28	Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies. Emerging Infectious Diseases, 2017, 23, 569-573.	4.3	50
29	A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. Journal of General Virology, 2017, 98, 1702-1712.	2.9	29
30	Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines. PLoS Neglected Tropical Diseases, 2016, 10, e0004854.	3.0	16
31	Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. American Journal of Tropical Medicine and Hygiene, 2016, 95, 741-745.	1.4	39
32	Predictors of dengue severity. Jornal De Pediatria (VersÃ£o Em PortuguÃas), 2016, 92, 429-431.	0.2	0
33	Dengue Vaccine Efficacy: Not a Zero Sum Game. Journal of Infectious Diseases, 2016, 214, 2014-2014.	4.0	11
34	Dengue vaccine and the 2016 Olympics. Lancet, The, 2016, 388, 237-238.	13.7	6
35	Predictors of dengue severity. Jornal De Pediatria, 2016, 92, 429-431.	2.0	4
36	Critique of World Health Organization Recommendation of a Dengue Vaccine. Journal of Infectious Diseases, 2016, 214, 1793-1795.	4.0	52

#	ARTICLE	IF	CITATIONS
37	Response to Hadinegoro et al.. Vaccine, 2016, 34, 4275.	3.8	3
38	The risks behind Dengvaxia recommendation. Lancet Infectious Diseases, The, 2016, 16, 882-883.	9.1	92
39	Is discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply. Lancet, The, 2016, 388, 1881-1882.	13.7	1
40	Dengue infection. Nature Reviews Disease Primers, 2016, 2, 16055.	30.5	415
41	Dengue vaccines: Are they safe for travelers?. Travel Medicine and Infectious Disease, 2016, 14, 378-383.	3.0	17
42	Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine, 2016, 34, 1643-1647.	3.8	143
43	Epidemiology of bladder stone of children: precipitating events. Urolithiasis, 2016, 44, 101-108.	2.0	16
44	The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. PLoS Neglected Tropical Diseases, 2016, 10, e0005179.	3.0	146
45	Pathogenesis of Dengue: Dawn of a New Era. F1000Research, 2015, 4, 1353.	1.6	63
46	Comment on "Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity" and "Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination". Science Translational Medicine, 2015, 7, 318e4.	12.4	3
47	Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiology and Molecular Biology Reviews, 2015, 79, 281-291.	6.6	69
48	Pathogenic Exploitation of Fc Activity. , 2014, , 333-350.		2
49	Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Human Pathology, 2014, 45, 1221-1233.	2.0	136
50	Consultation on dengue vaccines: Progress in understanding protection, 26â€“28 June 2013, Rockville, Maryland. Vaccine, 2014, 32, 3115-3121.	3.8	5
51	Stumbles on the path to dengue control. Lancet Infectious Diseases, The, 2014, 14, 661-662.	9.1	6
52	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology Spectrum, 2014, 2, .	3.0	225
53	Dengue vaccines. , 2013, , 1042-1051.		7
54	Identifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine, 2013, 31, 4501-4507.	3.8	96

#	ARTICLE	IF	CITATIONS
55	High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection. <i>Journal of Virology</i> , 2013, 87, 12562-12575.	3.4	92
56	Japanese encephalitis vaccines. , 2013, , 312-351.		19
57	Dengue Vascular Permeability Syndrome: What, No T Cells?. <i>Clinical Infectious Diseases</i> , 2013, 56, 900-901.	5.8	23
58	Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. <i>Archives of Virology</i> , 2013, 158, 1445-1459.	2.1	546
59	Dengue: The Syndromic Basis to Pathogenesis Research. Inutility of the 2009 WHO Case Definition. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 212-215.	1.4	30
60	Call to Action for Dengue Vaccine Failure. <i>Emerging Infectious Diseases</i> , 2013, 19, 1335-1337.	4.3	25
61	Controlling Dengue with Vaccines in Thailand. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1876.	3.0	74
62	Controversies in dengue pathogenesis. <i>Paediatrics and International Child Health</i> , 2012, 32, 5-9.	1.0	67
63	Dengue vaccine development: a 75% solution?. <i>Lancet, The</i> , 2012, 380, 1535-1536.	13.7	105
64	Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001â€“2002. <i>International Journal of Infectious Diseases</i> , 2012, 16, e198-e203.	3.3	29
65	Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1450.	3.0	31
66	Virus Role During Intraepidemic Increase in Dengue Disease Severity. <i>Vector-Borne and Zoonotic Diseases</i> , 2011, 11, 675-681.	1.5	28
67	New Japanese encephalitis vaccines: alternatives to production in mouse brain. <i>Expert Review of Vaccines</i> , 2011, 10, 355-364.	4.4	115
68	In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1188.	3.0	184
69	Dengue Fever and Dengue Hemorrhagic Fever. , 2011, , 1147-1150.e1.		4
70	New Vaccines for Japanese Encephalitis. <i>Current Infectious Disease Reports</i> , 2010, 12, 174-180.	3.0	19
71	Dengue: a continuing global threat. <i>Nature Reviews Microbiology</i> , 2010, 8, S7-S16.	28.6	1,506
72	Japanese Encephalitis: New Options for Active Immunization. <i>Clinical Infectious Diseases</i> , 2010, 50, 1155-1164.	5.8	84

#	ARTICLE	IF	CITATIONS
73	How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections. <i>Vaccine Journal</i> , 2010, 17, 1829-1835.	3.1	127
74	Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 712-722.	9.1	334
75	Japanese Encephalitis. , 2010, , 317-333.		2
76	Evaluation of Commercially Available Anti-Dengue Virus Immunoglobulin M Tests. <i>Emerging Infectious Diseases</i> , 2009, 15, 436-440.	4.3	188
77	Dengue 1 Virus and Dengue Hemorrhagic Fever, French Polynesia, 2001. <i>Emerging Infectious Diseases</i> , 2009, 15, 1265-1270.	4.3	23
78	Antibodies Determine Virulence in Dengue. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, E48-56.	3.8	67
79	Assessing the prognosis of dengue-infected patients. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	16
80	Dengue Virus-Mosquito Interactions. <i>Annual Review of Entomology</i> , 2008, 53, 273-291.	11.8	345
81	Pathogenesis: Risk Factors Prior to Infection. <i>Tropical Medicine</i> , 2008, , 219-256.	0.3	10
82	Japanese encephalitis vaccines. , 2008, , 311-352.		62
83	Dengue vaccines. , 2008, , 1155-1161.		4
84	Natural History of Dengue Virus (DENV) 1 and DENV 4 Infections: Reanalysis of Classic Studies. <i>Journal of Infectious Diseases</i> , 2007, 195, 1007-1013.	4.0	149
85	Dengue-The Case Definition Dilemma: A Commentary. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 291-292.	2.0	23
86	Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. <i>Vaccine</i> , 2007, 25, 5041-5045.	3.8	115
87	The burden of dengue infection. <i>Lancet, The</i> , 2007, 369, 1410-1411.	13.7	61
88	Dengue. <i>Lancet, The</i> , 2007, 370, 1644-1652.	13.7	1,236
89	Three commentaries on Corticosteroids for treating dengue shock syndrome™, with introduction by EBCH editor. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2007, 2, 1080-1086.	2.0	2
90	Neutralizing Antibodies after Infection with Dengue 1 Virus. <i>Emerging Infectious Diseases</i> , 2007, 13, 282-286.	4.3	99

#	ARTICLE	IF	CITATIONS
91	VOLUME REPLACEMENT IN INFANTS WITH DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME. American Journal of Tropical Medicine and Hygiene, 2006, 74, 684-691.	1.4	34
92	DENGUE HEMORRHAGIC FEVER CAUSED BY SEQUENTIAL DENGUE 1-3 VIRUS INFECTIONS OVER A LONG TIME INTERVAL: HAVANA EPIDEMIC, 2001-2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-1117.	1.4	114
93	Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-7.	1.4	53
94	More Dengue, More Questions. Emerging Infectious Diseases, 2005, 11, 740-741.	4.3	45
95	Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet, The, 2005, 366, 1375-1378.	13.7	109
96	Recombination and flavivirus vaccines: a commentary. Vaccine, 2005, 23, 2956-2958.	3.8	37
97	ASSOCIATION BETWEEN SEX, NUTRITIONAL STATUS, SEVERITY OF DENGUE HEMORRHAGIC FEVER, AND IMMUNE STATUS IN INFANTS WITH DENGUE HEMORRHAGIC FEVER. American Journal of Tropical Medicine and Hygiene, 2005, 72, 370-374.	1.4	81
98	Dengue Hemorrhagic Fever in Infants: A Study of Clinical and Cytokine Profiles. Journal of Infectious Diseases, 2004, 189, 221-232.	4.0	233
99	Cost-effectiveness of a pediatric dengue vaccine. Vaccine, 2004, 22, 1275-1280.	3.8	125
100	Neutralization and Antibody-Dependent Enhancement of Dengue Viruses. Advances in Virus Research, 2003, 60, 421-467.	2.1	617
101	BIOLOGIC PROPERTIES OF DENGUE VIRUSES FOLLOWING SERIAL PASSAGE IN PRIMARY DOG KIDNEY CELLS: STUDIES AT THE UNIVERSITY OF HAWAII. American Journal of Tropical Medicine and Hygiene, 2003, 69, 5-11.	1.4	62
102	Dengue. Current Opinion in Infectious Diseases, 2002, 15, 471-476.	3.1	124
103	Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet, The, 2002, 360, 310-312.	13.7	148
104	The future of dengue vaccines. Lancet, The, 2002, 360, 1243-1245.	13.7	123
105	Effect of age on outcome of secondary dengue 2 infections. International Journal of Infectious Diseases, 2002, 6, 118-124.	3.3	262
106	Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored. Emerging Infectious Diseases, 2002, 8, 1474-1479.	4.3	216
107	Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2002, 11, 223-227.	1.1	174
108	Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet, The, 2001, 358, 791-795.	13.7	154

#	ARTICLE	IF	CITATIONS
109	Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?. Lancet, The, 2000, 355, 1902-1903.	13.7	71
110	Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet, The, 1999, 354, 1431-1434.	13.7	260
111	RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND. American Journal of Epidemiology, 1984, 120, 653-669.	3.4	627
112	Absence of Dengue 2 Infection Enhancement in Human Sera Containing Japanese Encephalitis Antibodies. American Journal of Tropical Medicine and Hygiene, 1984, 33, 288-294.	1.4	14
113	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 654-665.	1.4	18
114	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 666-671.	1.4	12
115	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 672-678.	1.4	19
116	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 679-683.	1.4	28
117	Original Antigenic Sin in Dengue. American Journal of Tropical Medicine and Hygiene, 1983, 32, 154-156.	1.4	244
118	Comparison of P388D1 Mouse Macrophage Cell Line and Human Monocytes for Assay of Dengue-2 Infection-Enhancing Antibodies. American Journal of Tropical Medicine and Hygiene, 1983, 32, 157-163.	1.4	39
119	Cause of Primary Bladder Stone in England – A Retrospective Epidemiological Study. , 1981, , 325-328.		4
120	An explanation for enhanced virus plaque formation in chick embryo cells. Nature, 1980, 285, 504-505.	27.8	41
121	Immunological Parameters of Togavirus Disease Syndromes. , 1980, , 107-173.		78
122	Transmission of Dengue 1 and 2 Viruses in Greece in 1928 *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 635-637.	1.4	51
123	Enhancement of Dengue Virus Infection in Monocytes by Flavivirus Antisera *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 638-642.	1.4	134
124	Dengue Virus Replication Enhancement in Peripheral Blood Leukocytes from Immune Human Beings. Experimental Biology and Medicine, 1976, 151, 136-139.	2.4	63
125	Etiologies of the Experimental Dengues of Siler and Simmons *. American Journal of Tropical Medicine and Hygiene, 1974, 23, 974-982.	1.4	92
126	Studies on the Pathogenesis of Dengue Infection in Monkeys. II. Clinical Laboratory Responses to Heterologous Infection. Journal of Infectious Diseases, 1973, 128, 15-22.	4.0	170

#	ARTICLE	IF	CITATIONS
127	STUDIES ON THE IMMUNIZATION OF MONKEYS AGAINST DENGUE. American Journal of Tropical Medicine and Hygiene, 1973, 22, 365-374.	1.4	53
128	Rubella: Reinfection of Vaccinated and Naturally Immune Persons Exposed in an Epidemic. New England Journal of Medicine, 1970, 283, 771-778.	27.0	250
129	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962-1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 1022-1033.	1.4	55
130	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962-1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 954-971.	1.4	303
131	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962-1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 972-983.	1.4	97
132	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962-1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 984-996.	1.4	72
133	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962-1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 997-1021.	1.4	196
134	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1320-1328.	4.7	30
135	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1352-1361.	4.7	27
136	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1329-1339.	4.7	40
137	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1340-1351.	4.7	35
138	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1312-1319.	4.7	25
139	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1362-1368.	4.7	33
140	Shock associated with dengue infection. Journal of Pediatrics, 1966, 68, 448-456.	1.8	93
141	Recent Epidemics of Hemorrhagic Fever in Thailand: Observations Related to Pathogenesis of a "New" Dengue Disease. American Journal of Public Health and the Nation's Health, 1965, 55, 1386-1395.	0.3	45
142	Studies of hemostasis in Thai hemorrhagic fever. Journal of Pediatrics, 1965, 66, 918-926.	1.8	31
143	In vitro Recovery of Dengue Viruses from Naturally Infected Human Beings and Arthropods. Nature, 1964, 202, 931-932.	27.8	16
144	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. , 0, , 249-271.		25